Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Carcinoma, Hepatocellular 8Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Rectal Neoplasms 6Nasopharyngeal Carcinoma 6Melanoma 6Lymphoma, Extranodal NK-T-Cell 6Locally Advanced Rectal Cancer 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Cholangiocarcinoma 3Thyroid Neoplasms 2Nasopharyngeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Hemangiosarcoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Adenocarcinoma Of Esophagus 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

Filgrastim 4Ifosfamide 3Carboplatin 3Peripheral Blood Stem Cell Transplantation 2Immune Checkpoint Inhibitors 2Etoposide 2spartalizumab 1regorafenib 1perifosine 1pegfilgrastim 1pazopanib 1ivosidenib 1etoposide phosphate 1enasidenib 1drozitumab 1angiotensin I (1-7) 1alanosine 1abemaciclib 1Vincristine 1Trabectedin 1Topotecan 1Thiotepa 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Radiotherapy 1Radiosurgery 1Proton Therapy 1Pharmacogenomic Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Chondrosarcoma × spartalizumab × Clear all
NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Assaf-Harofeh Medical Center

Phase 2 Unknown
60 enrolled
GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡